Distinct Benefit of Overall Survival between Patients with Non-Small-Cell Lung Cancer Harboring EGFR Exon 19 Deletion and Exon 21 L858R Substitution

Publisher： Karger

E-ISSN： 1421-9794|62|3|151-158

ISSN： 0009-3157

Source： Chemotherapy, Vol.62, Iss.3, 2017-01, pp. : 151-158

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy

By  

Chemotherapy, Vol. 62, Iss. 4, 2017-04 ,pp. : 205-213

Karger

Access to resources Recommend Favorite

Phase II Study of Pemetrexed and Erlotinib in Pretreated Nonsquamous, Non-Small-Cell Lung Cancer Patients without an EGFR mutation

By  

Chemotherapy, Vol. 59, Iss. 6, 2014-07 ,pp. : 414-419

Karger

Access to resources Recommend Favorite

A Method for Biomarker Directed Survival Prediction in Advanced Non-Small-Cell Lung Cancer Patients Treated with Carboplatin-Based Therapy

By Chen Wei   Bepler Gerold  

Journal of Personalized Medicine, Vol. 3, Iss. 3, 2013-09 ,pp. : 251-262

MDPI

Access to resources Recommend Favorite

Prognostic Index for Survival in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Third-Generation Agents

By  

Chemotherapy, Vol. 62, Iss. 4, 2017-05 ,pp. : 239-245

Karger

Access to resources Recommend Favorite

Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK

By Rothschild Sacha I.  

Cancers, Vol. 7, Iss. 2, 2015-05 ,pp. : 930-949

MDPI

Access to resources Recommend Favorite